Article

Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy

Laboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA
Free Radical Biology and Medicine (Impact Factor: 5.74). 02/2010; 48(3):457-467. DOI: 10.1016/j.freeradbiomed.2009.11.022

ABSTRACT

Cisplatin is an important chemotherapeutic agent; however, its nephrotoxicity limits its clinical use. Enhanced inflammatory response and oxidative/nitrosative stress seem to play a key role in the development of cisplatin-induced nephropathy. Activation of cannabinoid-2 (CB2) receptors with selective agonists exerts anti-inflammatory and tissue-protective effects in various disease models. We have investigated the role of CB2 receptors in cisplatin-induced nephrotoxicity using the selective CB2 receptor agonist HU-308 and CB2 knockout mice. Cisplatin significantly increased inflammation (leukocyte infiltration, CXCL1/2, MCP-1, TNFα, and IL-1β levels) and expression of adhesion molecule ICAM-1 and superoxide-generating enzymes NOX2, NOX4, and NOX1 and enhanced ROS generation, iNOS expression, nitrotyrosine formation, and apoptotic and poly(ADP-ribose) polymerase-dependent cell death in the kidneys of mice, associated with marked histopathological damage and impaired renal function (elevated serum BUN and creatinine levels) 3 days after the administration of the drug. CB2 agonist attenuated the cisplatin-induced inflammatory response, oxidative/nitrosative stress, and cell death in the kidney and improved renal function, whereas CB2 knockouts developed enhanced inflammation and tissue injury. Thus, the endocannabinoid system, through CB2 receptors, protects against cisplatin-induced kidney damage by attenuating inflammation and oxidative/nitrosative stress, and selective CB2 agonists may represent a promising novel approach to preventing this devastating complication of chemotherapy.

Download full-text

Full-text

Available from: Pal Pacher
  • Source
    • "CB2R stimulation dampens LPS-induced pro-inflammatory cytokine production in the model of acute experimental sepsis in mice[10], reduces the inflammatory cells infiltration and attenuates fibrosis in cirrhotic rats[6], and prevents the development of skin and lung fibrosis in a mouse model of systemic sclerosis[11]. Conversely, CB2R knockouts developed enhanced inflammation and tissue injury[12], and inhibition of CB2R signaling augments bleomycin-induced dermal fibrosis in mice[13]. These evidences demonstrate that CB2R is closely involved in inflammatory response and tissue repair. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Skeletal muscle injuries repair typically is an overlapping event between inflammation and tissue repair. Our previous study has demonstrated that activation of cannabinoid receptor type 2 (CB2R) by JWH-133 alleviates fibrosis in the repair of rat skeletal muscle contusion. Meanwhile, accumulated data show that CB2R stimulation exerts anti-inflammatory property in sepsis and cystitis. However, the effects of CB2R on inflammatory cytokines in response to the repair of skeletal muscle contusion are still unknown. In this study, we used selective agonist or antagonist of CB2R to observe the role of CB2R on inflammation and fibrogenesis during the repair of contused skeletal muscles in rats. Our results revealed that treatment with Gp1a, a selective CB2R agonist, significantly decreased the infiltration of neutrophils and macrophages, the expression of pro-inflammatory cytokines MCP-1, TNF-α, IL-1β and IL-6, the expression of pro-fibrotic cytokines IL-4, IL-13, TGF-β and P-Smad3 while increased anti-fibrotic cytokine IL-10 production as compared with Vehicle. The opposite results were observed in the CB2R inhibition group with AM630. Our study demonstrated that CB2R orchestrates fibrogenesis through regulation of inflammatory response during the repair of skeletal muscle contusion.
    Full-text · Article · Jun 2015 · International journal of clinical and experimental pathology
  • Source
    • "The best known representative of this group is the endocannabinoid anandamide (N-arachidonoylethanolamine anandamide, AEA) (Alexander and Kendall, 2007; Correa et al., 2009; Pertwee et al., 2010). The cannabinoid (CB) 2 receptor (Alexander et al., 2013a) has been linked to the anti-inflammatory effects of anandamide and other endocannabinoids and is predominantly expressed by cells of the immune system (Bátkai et al., 2007; Csóka et al., 2009; Mukhopadhyay et al., 2010; Basu and Dittel, 2011). At the same time it is clear that not all NAEs exclusively bind to CB1 or CB2 receptors, but often also (or instead) show affinity for GPR55, GPR18, GPR119, transient receptor potential channel vanilloid subtype 1 (TRPV1; see Alexander et al., 2013b) or PPARs (Alexander and Kendall, 2007; Di Marzo et al., 2007; Pertwee et al., 2010; Maccarrone, 2013; for nomenclature see Alexander et al., 2013c). "
    [Show abstract] [Hide abstract]
    ABSTRACT: DHEA (N-docosahexaenoylethanolamine) is the ethanolamine conjugate of the long chain polyunsaturated n-3 fatty acid DHA (docosahexaenoic; 22 : 6n-3). Its concentration in animal tissues and human plasma increases when diets rich in fish or krill oil are consumed. DHEA displays anti-inflammatory properties in vitro and was found to be released during an inflammatory response in mice. Here we further examine possible targets involved in the immune-modulating effects of DHEA. Antagonists for CB1 , CB2 and PPAR were used to explore effects of DHEA on NO release by LPS-stimulated RAW264.7 cells. Possible involvement of CB2 receptors was also studied by comparing effects in LPS-stimulated peritoneal macrophages obtained from CB2 (-/-) and CB(+/+) mice. Effects on NF-κB activation were determined using a reporter cell line. To study DHEA effects on COX-2 and LOX activity, 21 different eicosanoids produced by LPS-stimulated RAW264.7 cells were quantified by LC-MS/MS. Finally, effects on mRNA expression profiles were analysed using gene arrays followed by Ingenuity(®) Pathways Analysis. Effects of DHEA on NO release appeared to be independent from CB1 , CB2 or PPAR receptors. NF-κB and IFNβ, key elements of the MyD88-dependent and MyD88-independent pathways were not decreased. By contrast, DHEA significantly reduced levels of several COX-2 generated eicosanoids. Gene expression analysis provided support for an effect on COX-2-mediated pathways. Our findings suggest that anti-inflammatory effects of DHEA in macrophages are predominantly taking place via inhibition of eicosanoids produced through COX-2.
    Full-text · Article · Apr 2014 · British Journal of Pharmacology
  • Source
    • "The activation of the CB2 receptor seems indeed to be associated with a reduced expression of iNOS [57]. Additionally, CB2 stimulation seems to suppress the release of pro-inflammatory factors such as NO and tumor necrosis factor alpha (TNF-α) in macrophages [58]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Experimental animal models of migraine have suggested the existence of interactions between the endocannabinoid system and pain mediation in migraine. Extensive evidence has demonstrated a role for the cannabinoid-1 (CB1) receptor in antinociception. However, recent research suggests that also CB2 receptors, especially located outside the central nervous system, play a role in the perception of pain. Systemic administration of nitroglycerin (NTG) consistently induces spontaneous-like headache attacks in migraneurs; in the rat, systemic NTG induces a condition of hyperalgesia, probably through the activation of cerebral/spinal structures involved in nociceptive transmission. In this study we evaluated the role of CB2 receptors in two animal models of pain that may be relevant for migraine: the tail flick test and the formalin test performed during NTG-induced hyperalgesia. The study was performed in male Sprague-Dawley rats pre-treated with NTG (10 mg/kg, i.p.) or vehicle (4 hours before) and treated with the CB2 agonist AM1241 o dimethylsulfoxide (DMSO) 60 minutes before both the tail flick test and the formalin test. AM1241 showed a significant analgesic effect in baseline conditions in both tests. Furthermore, when administered 3 hours after NTG administration, AM1241 at both doses significantly reduced the total number of flinches/shakes during phase II of the test. These findings suggest that the pharmacological manipulation of the CB2 receptor may represent a potential therapeutic tool for the treatment of migraine.
    Full-text · Article · Mar 2014 · The Journal of Headache and Pain
Show more